A comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over seven-day storage.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Onundarson, Pall T
Sigurjonsson, Olafur E
Halldorsdottir, Anna M
MetadataShow full item record
CitationMikaelsdottir M, Vidarsson B, Runarsson G, Bjarnadottir U, Onundarson PT, Sigurjonsson OE, Halldorsdottir AM. A comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over seven-day storage. Transfusion. 2020 Nov 9. doi: 10.1111/trf.16176.
ÚtdrátturBackground: Therapeutic phlebotomy is the standard treatment of hereditary hemochromatosis (HH), the most common genetic disease in people of Northern European descent. Red cell concentrates from HH donors have been reported safe for transfusion, but little data is available on the storage properties of platelet concentrates from HH donors. Study design and methods: Whole blood was collected from 10 healthy individuals and 10 newly diagnosed HH patients with elevated serum ferritin. Platelet-rich plasma (PRP) was prepared and split into four 20-mL units. Platelet quality tests were performed on days 0, 1, 3, 5, and 7 of storage, including platelet aggregation (ADP, arachidonic acid, collagen, and epinephrine agonists), blood gas analysis, flow cytometry (CD41, CD42b, and CD62P expression), and ELISA (sCD40L and sCD62p in supernatant). Results: Mean serum ferritin levels were higher in HH patients than in controls (847.5 vs 45.8 ng/mL, P < .001). Overall, no difference in quality test results was observed between the two study groups over 7-day storage (P > .05), including blood gas analysis, platelet aggregation, and expression of surface (CD62p and CD42b) and secreted (sCD62P and sCD40L) activation markers. Expected alterations in metabolic (CO2 and glucose decrease, O2 and lactate increase, P < .001) and platelet activation markers (CD42b decrease, CD62P increase, P < .05) over time were observed in both groups. Conclusion: Although these findings indicate that platelets of individuals with HH are comparable to platelets from healthy donors, more extensive studies are needed before definite conclusions can be drawn.
Lu00FDsingTo access publisher's full text version of this article click on the hyperlink below
Rights© 2020 AABB.
- Comparison of random-donor platelet concentrates prepared from whole blood units and platelets prepared from single-donor apheresis collections.
- Authors: Sloand EM, Yu M, Klein HG
- Issue date: 1996 Nov-Dec
- Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage.
- Authors: Skripchenko A, Kurtz J, Moroff G, Wagner SJ
- Issue date: 2008 Jul
- In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.
- Authors: Apelseth TØ, Bruserud Ø, Wentzel-Larsen T, Bakken AM, Bjørsvik S, Hervig T
- Issue date: 2007 Apr
- Comparison of cytokine levels and metabolic parameters of stored platelet concentrates of the Fundação Hemominas, Belo Horizonte, Brazil.
- Authors: Costa EJ, Guimarães TM, de Almeida NC, de Toledo Vde P
- Issue date: 2012
- Changes in platelet morphology and function during 24 hours of storage.
- Authors: Braune S, Walter M, Schulze F, Lendlein A, Jung F
- Issue date: 2014